CAMBISeq

CAMBISeq is a test that utilizes an advanced technique called Next-Generation Sequencing (NGS) to uncover the genetic mutations of a tumor by analysis of DNA and RNA to provide clinicians with important insights.

The CAMBISeq, or cancer analysis, mutational burden, and instability sequencing test, is used to identify variants in 500 genes that our scientists use as biomarkers to assess their sensitivity to immunotherapy. The results can predict how well a patient will respond to types of immunotherapy.

CAMBISeq is suitable for all patients who have a confirmed cancer diagnosis. The test can be used by clinicians to identify the best and most effective combinations of cancer treatments.

How does CAMBISeq work?

• CAMBISeq uses next-generation sequencing technology in circulating tumor cells and analyses more than 500 genes at DNA and RNA level, providing useful information for sensitivity in immunotherapy and targeted therapies.
• It digs deep into a patient’s genetic makeup, covering over 500 genes and thousands of variants that can significantly impact the success of cancer treatments.
• It assesses multivariant types in a single assay and detects variants at low variant allele frequency. These specific biomarkers guide clinicians toward treatments with the highest potential to combat the patient’s unique cancer.
• It covers different types of cancer (lung, breast, colon, myeloid, sarcoma etc.) in one test.

How does CAMBISeq help?

• CAMBISeq identifies variants in over 500 genes, detects fusions, and calculates the Tumor Mutational Burden (TMB) and Microsatellite Instability Status (MSI).
• Identification of specific mutations that help in designing personalized targeted therapies that have the highest chances of treatment.
• Provides a Tumour Mutational Burden score, an emerging quantitative genomic information used to predict sensitivity to checkpoint inhibitors (immunotherapies).